UBS AM
CRSP icon

UBS AM’s CRISPR Therapeutics CRSP Stock Holding History

UBS AM’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.1K Sell
1,193
-156,203
-99% -$8.23M ﹤0.01% 2896
2026
Q1 		$7.49M Buy
157,396
+8,495
+6% +$448K ﹤0.01% 1364
2025
Q4 		$7.81M Buy
+148,901
New +$8.92M ﹤0.01% 1239
2025
Q3 		– Sell
-964,690
Closed -$46.9M – 2357
2025
Q2 		$46.9M Sell
964,690
-988,061
-51% -$38.2M 0.01% 720
2025
Q1 		$66.5M Buy
1,952,751
+1,262,560
+183% +$53.5M 0.02% 626
2024
Q4 		$27.2M Buy
690,191
+13,865
+2% +$655K 0.01% 839
2024
Q3 		$31.8M Sell
676,326
-17,632
-3% -$895K 0.01% 791
2024
Q2 		$37.5M Buy
693,958
+583,493
+528% +$33.8M 0.01% 682
2024
Q1 		$7.53M Buy
110,465
+14,515
+15% +$1.04M ﹤0.01% 1100
2023
Q4 		$6.01M Buy
95,950
+2,825
+3% +$156K ﹤0.01% 1174
2023
Q3 		$4.23M Buy
93,125
+10,839
+13% +$560K ﹤0.01% 1287
2023
Q2 		$3.72M Hold
82,286
– – ﹤0.01% 1366
2023
Q1 		$3.72M Buy
82,286
+6,380
+8% +$310K ﹤0.01% 1366
2022
Q4 		$3.09M Buy
75,906
+120
+0.2% +$6.37K ﹤0.01% 1346
2022
Q3 		$4.95M Sell
75,786
-57,368
-43% -$4.16M ﹤0.01% 1206
2022
Q2 		$8.09M Buy
133,154
+13,827
+12% +$813K ﹤0.01% 1045
2022
Q1 		$7.49M Sell
119,327
-206
-0.2% -$12.9K ﹤0.01% 1182
2021
Q4 		$9.06M Buy
119,533
+5,113
+4% +$447K ﹤0.01% 1161
2021
Q3 		$12.8M Sell
114,420
-2,793
-2% -$351K 0.01% 997
2021
Q2 		$19M Sell
117,213
-23,841
-17% -$2.9M 0.01% 898
2021
Q1 		$17.2M Buy
141,054
+34,308
+32% +$5.18M 0.01% 901
2020
Q4 		$16.3M Sell
106,746
-13,846
-11% -$1.64M 0.01% 899
2020
Q3 		$10.1M Sell
120,592
-18,438
-13% -$1.64M 0.01% 939
2020
Q2 		$10.2M Buy
139,030
+8,702
+7% +$509K 0.01% 901
2020
Q1 		$5.53M Buy
+130,328
New +$6.73M ﹤0.01% 1021

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS AM's CRSP Position: Q2 2026 in Review

UBS AM reduced its CRISPR Therapeutics (CRSP) stake by 99% in Q2 2026, selling an estimated $8.23M and leaving 1,193 shares worth $65.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2896.

UBS AM first reported a position in CRSP in Q1 2020 and has held it in 25 quarters since. The position peaked at $66.5M in Q1 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • UBS AM held 1,193 shares of CRISPR Therapeutics worth $65.1K as of Q2 2026.
  • UBS AM sold 156,203 CRISPR Therapeutics shares in Q2 2026, an estimated $8.23M.
  • CRISPR Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2896 holding.
  • UBS AM first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 25 quarters since.
  • UBS AM's CRISPR Therapeutics position peaked at $66.5M in Q1 2025.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.